Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 6361479, 14 pages
https://doi.org/10.1155/2017/6361479
Review Article

Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis

1Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun 130021, China
2Department of Neurobiology, Care Sciences and Society, Karolinska Institute, 141 86 Stockholm, Sweden
3Department of Neurosurgery, The First Hospital of Jilin University, Jilin University, Changchun 130021, China

Correspondence should be addressed to Xu Wang

Received 19 February 2017; Accepted 4 April 2017; Published 18 June 2017

Academic Editor: Yona Keisari

Copyright © 2017 Cai-yun Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Dalmau, E. Tuzun, H. Y. Wu et al., “Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma,” Annals of Neurology, vol. 61, no. 1, pp. 25–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. M. S. Gable, H. Sheriff, J. Dalmau, D. H. Tilley, and C. A. Glaser, “The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project,” Clinical Infectious Diseases, vol. 54, no. 7, pp. 899–904, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Desena, D. Graves, W. Warnack, and B. M. Greenberg, “Herpes simplex encephalitis as a potential cause of anti-N-methyl-D-aspartate receptor antibody encephalitis: report of 2 cases,” JAMA Neurology, vol. 71, no. 3, pp. 344–346, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Dalmau, A. J. Gleichman, E. G. Hughes et al., “Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies,” Lancet Neurology, vol. 7, no. 12, pp. 1091–1098, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Dalmau, E. Lancaster, E. Martinez-Hernandez, M. R. Rosenfeld, and R. Balice-Gordon, “Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis,” Lancet Neurology, vol. 10, no. 1, pp. 63–74, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. N. R. Florance, R. L. Davis, C. Lam et al., “Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents,” Annals of Neurology, vol. 66, no. 1, pp. 11–18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. E. H. Moscato, X. Peng, A. Jain, T. D. Parsons, J. Dalmau, and R. J. Balice-Gordon, “Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis,” Annals of Neurology, vol. 76, no. 1, pp. 108–119, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. E. G. Hughes, X. Peng, A. J. Gleichman et al., “Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis,” The Journal of Neuroscience, vol. 30, no. 17, pp. 5866–5875, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Dalmau and M. R. Rosenfeld, “Paraneoplastic syndromes of the CNS,” Lancet Neurology, vol. 7, no. 4, pp. 327–340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Gabilondo, A. Saiz, L. Galan et al., “Analysis of relapses in anti-NMDAR encephalitis,” Neurology, vol. 77, no. 10, pp. 996–999, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. J. Titulaer, L. McCracken, I. Gabilondo et al., “Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study,” Lancet Neurology, vol. 12, no. 2, pp. 157–165, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Granerod, H. E. Ambrose, N. W. S. Davies et al., “Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study,” The Lancet Infectious Diseases, vol. 10, no. 12, pp. 835–844, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Pruss, J. Dalmau, L. Harms et al., “Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin,” Neurology, vol. 75, no. 19, pp. 1735–1739, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Lim, S. T. Lee, K. H. Jung et al., “Anti-N-methyl-D-aspartate receptor encephalitis in Korea: clinical features, treatment, and outcome,” Journal of Clinical Neurophysiology, vol. 10, no. 2, pp. 157–161, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Vitaliani, W. Mason, B. Ances, T. Zwerdling, Z. Jiang, and J. Dalmau, “Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma,” Annals of Neurology, vol. 58, no. 4, pp. 594–604, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Wang, J. M. Li, F. Y. Hu et al., “Anti-NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in Southwest China,” European Journal of Neurology, vol. 23, no. 3, pp. 621–629, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Armangue, F. Leypoldt, I. Malaga et al., “Herpes simplex virus encephalitis is a trigger of brain autoimmunity,” Annals of Neurology, vol. 75, no. 2, pp. 317–323, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. D. R. Lynch, N. J. Anegawa, T. Verdoorn, and D. B. Pritchett, “N-methyl-D-aspartate receptors: different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents,” Molecular Pharmacology, vol. 45, no. 3, pp. 540–545, 1994. View at Google Scholar
  19. E. A. Waxman and D. R. Lynch, “N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease,” The Neuroscientist, vol. 11, no. 1, pp. 37–49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. J. T. Coyle, “Glutamate and schizophrenia: beyond the dopamine hypothesis,” Cellular and Molecular Neurobiology, vol. 26, no. 4–6, pp. 365–384, 2006. View at Publisher · View at Google Scholar
  21. N. Gresa-Arribas, M. J. Titulaer, A. Torrents et al., “Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study,” Lancet Neurology, vol. 13, no. 2, pp. 167–177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Manto, J. Dalmau, A. Didelot, V. Rogemond, and J. Honnorat, “In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction,” Orphanet Journal of Rare Diseases, vol. 5, no. 1, p. 31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Planaguma, F. Leypoldt, F. Mannara et al., “Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice,” Brain, vol. 138, Part 1, pp. 94–109, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Wright, K. Hashemi, L. Stasiak et al., “Epileptogenic effects of NMDAR antibodies in a passive transfer mouse model,” Brain, vol. 138, Part 11, pp. 3159–3167, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. J. I. Byun, S. T. Lee, J. Moon et al., “Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-D-aspartate receptor encephalitis,” Journal of Neuroimmunology, vol. 297, pp. 141–147, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Miossec, T. Korn, and V. K. Kuchroo, “Interleukin-17 and type 17 helper T cells,” The New England Journal of Medicine, vol. 361, no. 9, pp. 888–898, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Huppert, D. Closhen, A. Croxford et al., “Cellular mechanisms of IL-17-induced blood-brain barrier disruption,” The FASEB Journal, vol. 24, no. 4, pp. 1023–1034, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Correale and M. Fiol, “Activation of humoral immunity and eosinophils in neuromyelitis optica,” Neurology, vol. 63, no. 12, pp. 2363–2370, 2004. View at Publisher · View at Google Scholar
  29. N. Chihara, T. Aranami, W. Sato et al., “Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 9, pp. 3701–3706, 2011. View at Google Scholar
  30. H. Ogura, M. Murakami, Y. Okuyama et al., “Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction,” Immunity, vol. 29, no. 4, pp. 628–636, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Leypoldt, R. Hoftberger, M. J. Titulaer et al., “Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response,” JAMA Neurology, vol. 72, no. 2, pp. 180–186, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. Z. Liba, J. Kayserova, M. Elisak et al., “Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid,” Journal of Neuroinflammation, vol. 13, no. 1, p. 55, 2016. View at Google Scholar
  33. E. Tüzün, L. Zhou, J. M. Baehring, S. Bannykh, M. R. Rosenfeld, and J. Dalmau, “Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma,” Acta Neuropathologica, vol. 118, no. 6, pp. 737–743, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. G. S. Day, S. Laiq, D. F. Tang-Wai, and D. G. Munoz, “Abnormal neurons in teratomas in NMDAR encephalitis,” JAMA Neurology, vol. 71, no. 6, pp. 717–724, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Skoldenberg, E. Aurelius, A. Hjalmarsson et al., “Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults,” Journal of Neurology, vol. 253, no. 2, pp. 163–170, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Armangue, M. J. Titulaer, I. Malaga et al., “Spanish anti Nm-DAREWG. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients,” The Journal of Pediatrics, vol. 162, no. 4, pp. 850–856.e2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Westman, M. Studahl, C. Ahlm et al., “N-methyl-D-aspartate receptor autoimmunity affects cognitive performance in herpes simplex encephalitis,” Clinical Microbiology and Infection, vol. 22, no. 11, pp. 934–940, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Hacohen, K. Deiva, P. Pettingill et al., “N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse,” Movement Disorders, vol. 29, no. 1, pp. 90–96, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Leypoldt, M. J. Titulaer, E. Aguilar et al., “Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report,” Neurology, vol. 81, no. 18, pp. 1637–1639, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. S. S. Mohammad, K. Sinclair, S. Pillai et al., “Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-methyl-D-aspartate receptor or dopamine-2 receptor,” Movement Disorders, vol. 29, no. 1, pp. 117–122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Koksal, S. Baybas, B. Mutluay, Y. Altunkaynak, and A. Keskek, “A case of NMDAR encephalitis misdiagnosed as postpartum psychosis and neuroleptic malignant syndrome,” Neurological Sciences, vol. 36, no. 7, pp. 1257-1258, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Steiner, M. Walter, W. Glanz et al., “Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis,” JAMA Psychiatry, vol. 70, no. 3, pp. 271–278, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Huang, Y. Kang, B. Zhang et al., “Anti-N-methyl-D-aspartate receptor encephalitis in a patient with a 7-year history of being diagnosed as schizophrenia: complexities in diagnosis and treatment,” Neuropsychiatric Disease and Treatment, vol. 11, pp. 1437–1442, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Mirabelli-Badenier, R. Biancheri, G. Morana et al., “Anti-NMDAR encephalitis misdiagnosed as Hashimoto’s encephalopathy,” European Journal of Paediatric Neurology, vol. 18, no. 1, pp. 72–74, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Greiner, J. L. Leach, K. H. Lee, and D. A. Krueger, “Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome,” Seizure, vol. 20, no. 3, pp. 266–270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Sartori, M. Nosadini, E. Cesaroni et al., “Paediatric anti-N-methyl-D-aspartate receptor encephalitis: the first Italian multicenter case series,” European Journal of Paediatric Neurology, vol. 19, no. 4, pp. 453–463, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. M. J. Titulaer and J. Dalmau, “Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men,” Neurology, vol. 82, no. 7, pp. 550-551, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. M. S. Kayser, M. J. Titulaer, N. Gresa-Arribas, and J. Dalmau, “Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis,” JAMA Neurology, vol. 70, no. 9, pp. 1133–1139, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Viaccoz, V. Desestret, F. Ducray et al., “Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis,” Neurology, vol. 82, no. 7, pp. 556–563, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. X. Finne Lenoir, C. Sindic, V. van Pesch et al., “Anti-N-methyl-D-aspartate receptor encephalitis with favorable outcome despite prolonged status epilepticus,” Neurocritical Care, vol. 18, no. 1, pp. 89–92, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Johnson, C. Henry, A. J. Fessler, and J. Dalmau, “Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus,” Neurology, vol. 75, no. 16, pp. 1480–1482, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. F. W. Drislane, A. S. Blum, M. R. Lopez, S. Gautam, and D. L. Schomer, “Duration of refractory status epilepticus and outcome: loss of prognostic utility after several hours,” Epilepsia, vol. 50, no. 6, pp. 1566–1571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. J. F. Baizabal-Carvallo, A. Stocco, E. Muscal, and J. Jankovic, “The spectrum of movement disorders in children with anti-NMDA receptor encephalitis,” Movement Disorders, vol. 28, no. 4, pp. 543–547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. T. J. Kleinig, P. D. Thompson, W. Matar et al., “The distinctive movement disorder of ovarian teratoma-associated encephalitis,” Movement Disorders, vol. 23, no. 9, pp. 1256–1261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. T. M. Nazif, J. Vazquez, L. S. Honig, and J. M. Dizon, “Anti-N-methyl-D-aspartate receptor encephalitis: an emerging cause of centrally mediated sinus node dysfunction,” Europace, vol. 14, no. 8, pp. 1188–1194, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Rubio-Agusti, J. Dalmau, T. Sevilla, M. Burgal, E. Beltran, and L. Bataller, “Isolated hemidystonia associated with NMDA receptor antibodies,” Movement Disorders, vol. 26, no. 2, pp. 351-352, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Hacohen, N. Dlamini, T. Hedderly et al., “N-methyl-D-aspartate receptor antibody-associated movement disorder without encephalopathy,” Developmental Medicine and Child Neurology, vol. 56, no. 2, pp. 190–193, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Niehusmann, J. Dalmau, C. Rudlowski et al., “Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy,” Archives of Neurology, vol. 66, no. 4, pp. 458–464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Erazo, J. Gonzalez, C. Quintanilla et al., “Subacute anti-N-methyl-D-aspartate receptor encephalitis. A series of 13 paediatric cases,” Revista Chilena de Pediatría, vol. 87, no. 6, pp. 487–493, 2016. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Vural, E. M. Arsava, N. Dericioglu, and M. A. Topcuoglu, “Central neurogenic hyperventilation in anti-NMDA receptor encephalitis,” Internal Medicine, vol. 51, no. 19, pp. 2789–2792, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. J. C. van Swieten, P. J. Koudstaal, M. C. Visser, H. J. Schouten, and J. van Gijn, “Interobserver agreement for the assessment of handicap in stroke patients,” Stroke, vol. 19, no. 5, pp. 604–607, 1988. View at Publisher · View at Google Scholar
  62. M. J. Titulaer, L. McCracken, I. Gabilondo et al., “Late-onset anti-NMDA receptor encephalitis,” Neurology, vol. 81, no. 12, pp. 1058–1063, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Hara, A. Morita, S. Kamei et al., “Anti-N-methyl-D-aspartate receptor encephalitis associated with carcinosarcoma with neuroendocrine differentiation of the uterus,” Journal of Neurology, vol. 258, no. 7, pp. 1351–1353, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. V. Afanasiev, M. L. Brechemier, W. Boisseau et al., “Anti-NMDA receptor antibody encephalitis and neuroendocrine pancreatic tumor: causal link?” Neurology, vol. 87, no. 1, pp. 112-113, 2016. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Y. Wu, X. J. He, M. L. Zhang, Y. Y. Shi, and J. W. Zhang, “Anti-N-methyl-D-aspartate receptor encephalitis with lung adenocarcinoma,” Neurological Sciences, vol. 37, no. 9, pp. 1573–1575, 2016. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Joe and J. Desai, “An atypical case of anti-N-methyl-D-aspartate receptor encephalitis,” Pediatric Neurology, vol. 63, pp. 80-81, 2016. View at Publisher · View at Google Scholar · View at Scopus
  67. T. J. Williams, D. R. Benavides, K. A. Patrice et al., “Association of autoimmune encephalitis with combined Immune checkpoint inhibitor treatment for metastatic cancer,” JAMA Neurology, vol. 73, no. 8, pp. 928–933, 2016. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Salam, T. Lavin, and A. Turan, “Limbic encephalitis following immunotherapy against metastatic malignant melanoma,” BML Case Reports, vol. 2016, 2016. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Becquart, G. Ryckewaert, E. Desmedt, L. Defebvre, E. Le Rhun, and L. Mortier, “Limbic encephalitis: a new paraneoplastic auto-immune manifestation associated with metastatic melanoma?” Annales de Dermatologie et de Vénéréologie, vol. 140, no. 4, pp. 278–281, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Armangue, M. J. Titulaer, L. Sabater et al., “A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma,” Annals of Neurology, vol. 75, no. 3, pp. 435–441, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. S. R. Irani, K. Bera, P. Waters et al., “N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes,” Brain, vol. 133, Part 6, pp. 1655–1667, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. X. Huang, C. Fan, J. Wu et al., “Clinical analysis on anti-N-methyl-D-aspartate receptor encephalitis cases: Chinese experience,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 10, pp. 18927–18935, 2015. View at Google Scholar
  73. R. Wang, H. Z. Guan, H. T. Ren, W. Wang, Z. Hong, and D. Zhou, “CSF findings in patients with anti-N-methyl-D-aspartate receptor-encephalitis,” Seizure, vol. 29, pp. 137–142, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. M. J. Titulaer, R. Hoftberger, T. Iizuka et al., “Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis,” Annals of Neurology, vol. 75, no. 3, pp. 411–428, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Finke, U. A. Kopp, M. Scheel et al., “Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis,” Annals of Neurology, vol. 74, no. 2, pp. 284–296, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Gunther, S. Brodoehl, O. W. Witte, M. Freesmeyer, J. O. Dalmau, and C. Redecker, “Atypical posthypoxic MRI changes in hypermetabolic regions in anti-NMDA-receptor encephalitis,” Neurology, vol. 79, no. 7, pp. 720-721, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. S. E. Schmitt, K. Pargeon, E. S. Frechette, L. J. Hirsch, J. Dalmau, and D. Friedman, “Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis,” Neurology, vol. 79, no. 11, pp. 1094–1100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. G. Mackay, K. Ahmad, J. Stone et al., “NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease,” Journal of Neurology, vol. 259, no. 9, pp. 1979–1981, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. M. S. Zandi, S. R. Irani, B. Lang et al., “Disease-relevant autoantibodies in first episode schizophrenia,” Journal of Neurology, vol. 258, no. 4, pp. 686–688, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. H. C. Hansen, C. Klingbeil, J. Dalmau, W. Li, B. Weissbrich, and K. P. Wandinger, “Persistent intrathecal antibody synthesis 15 years after recovering from anti-N-methyl-D-aspartate receptor encephalitis,” JAMA Neurology, vol. 70, no. 1, pp. 117–119, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Alexopoulos, M. L. Kosmidis, J. Dalmau, and M. C. Dalakas, “Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies,” Journal of Neurology, vol. 258, no. 8, pp. 1568–1570, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Castillo-Gomez, B. Oliveira, D. Tapken et al., “All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class,” Molecular Psychiatry, 2016. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Zerche, K. Weissenborn, C. Ott et al., “Preexisting serum autoantibodies against the NMDAR subunit NR1 modulate evolution of lesion size in acute ischemic stroke,” Stroke, vol. 46, no. 5, pp. 1180–1186, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. E. Castillo-Gomez, A. Kastner, J. Steiner et al., “The brain as immunoprecipitator of serum autoantibodies against N-methyl-D-aspartate receptor subunit NR1,” Annals of Neurology, vol. 79, no. 1, pp. 144–151, 2016. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Busse, M. Busse, B. Brix et al., “Seroprevalence of N-methyl-D-aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders and in dementia patients,” European Archives of Psychiatry and Clinical Neuroscience, vol. 264, no. 6, pp. 545–550, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Doss, K. P. Wandinger, B. T. Hyman et al., “High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types,” Annals of Clinical Translational Neurology, vol. 1, no. 10, pp. 822–832, 2014. View at Publisher · View at Google Scholar
  87. C. Hammer, B. Stepniak, A. Schneider et al., “Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood brain barrier integrity,” Neurology, Psychiatry and Brain Research, vol. 20, no. 10, pp. 10-11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. L. Dahm, C. Ott, J. Steiner et al., “Seroprevalence of autoantibodies against brain antigens in health and disease,” Annals of Neurology, vol. 76, no. 1, pp. 82–94, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Graus, M. J. Titulaer, R. Balu et al., “A clinical approach to diagnosis of autoimmune encephalitis,” Lancet Neurology, vol. 15, no. 4, pp. 391–404, 2016. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Lekoubou, A. Viaccoz, A. Didelot et al., “Anti-N-methyl-D-aspartate receptor encephalitis with acute disseminated encephalomyelitis-like MRI features,” European Journal of Neurology, vol. 19, no. 2, pp. e16–e17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. J. J. Luo, H. Lv, W. Sun et al., “Anti-N-methyl-D-aspartate receptor encephalitis in a patient with neuromyelitis optica spectrum disorders,” Multiple Sclerosis and Related Disorders, vol. 8, pp. 74–77, 2016. View at Publisher · View at Google Scholar · View at Scopus
  92. M. C. Kruer, T. K. Koch, D. N. Bourdette et al., “NMDA receptor encephalitis mimicking seronegative neuromyelitis optica,” Neurology, vol. 74, no. 18, pp. 1473–1475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Pennington, S. Livingstone, C. Santosh, and S. Razvi, “N-methyl D-aspartate receptor antibody encephalitis associated with myelitis,” Journal of the Neurological Sciences, vol. 317, no. 1–2, pp. 151–153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Takeda, H. Shimada, A. Tamura et al., “A case of anti-N-methyl-D-aspartate receptor encephalitis with multiple sclerosis-like demyelinated lesions,” Multiple Sclerosis and Related Disorders, vol. 3, no. 3, pp. 391–397, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. Hacohen, M. Absoud, M. Woodhall et al., “Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 85, no. 4, pp. 456–461, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. S. A. Lipton, “NMDA receptors, glial cells, and clinical medicine,” Neuron, vol. 50, no. 1, pp. 9–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Arboleya, A. Clemente, S. Deng et al., “Anti-NMDAR antibodies in new-onset psychosis. Positive results in an HIV-infected patient,” Brain, Behavior, and Immunity, vol. 56, pp. 56–60, 2016. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Seki, S. Suzuki, T. Iizuka et al., “Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 79, no. 3, pp. 324–326, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Kadoya, H. Onoue, A. Kadoya, K. Ikewaki, and K. Kaida, “Refractory status epilepticus caused by anti-NMDA receptor encephalitis that markedly improved following combination therapy with rituximab and cyclophosphamide,” Internal Medicine, vol. 54, no. 2, pp. 209–213, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Ishiura, S. Matsuda, M. Higashihara et al., “Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab,” Neurology, vol. 71, no. 23, pp. 1921–1923, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. T. Iizuka, F. Sakai, T. Ide et al., “Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal,” Neurology, vol. 70, no. 7, pp. 504–511, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. A. J. Houtrow, M. Bhandal, N. R. Pratini, L. Davidson, and J. A. Neufeld, “The rehabilitation of children with anti-N-methyl-D-aspartate-receptor encephalitis: a case series,” American Journal of Physical Medicine & Rehabilitation, vol. 91, no. 5, pp. 435–441, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Masghati, M. Nosratian, and O. Dorigo, “Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy,” Obstetrics and Gynecology, vol. 123, Supplement 2, no. 2, Part 2, pp. 433–435, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. S. R. Mehr, R. C. Neeley, M. Wiley, and A. B. Kumar, “Profound autonomic instability complicated by multiple episodes of cardiac asystole and refractory bradycardia in a patient with anti-NMDA encephalitis,” Case Reports in Neurological Medicine, vol. 2016, Article ID 7967526, 5 pages, 2016. View at Publisher · View at Google Scholar
  105. S. Tatencloux, P. Chretien, V. Rogemond, J. Honnorat, M. Tardieu, and K. Deiva, “Intrathecal treatment of anti-N-methyl-D-aspartate receptor encephalitis in children,” Developmental Medicine and Child Neurology, vol. 57, no. 1, pp. 95–99, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. R. Rangel-Guerra, C. R. Camara-Lemarroy, G. Garcia-Arellano, A. C. Rodriguez-Martinez, and D. A. Galarza-Delgado, “Could coenzyme Q10 supplementation have a role in the treatment of anti-NMDA receptor encephalitis?” Acta Neurologica Belgica, vol. 115, no. 1, pp. 85-86, 2015. View at Publisher · View at Google Scholar · View at Scopus
  107. J. A. Panzer and D. R. Lynch, “Neuroimmunology: treatment of anti-NMDA receptor encephalitis—time to be bold?” Nature Reviews. Neurology, vol. 9, no. 4, pp. 187–189, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. S. L. Tham and K. H. Kong, “A case of anti-NMDAR (N-methyl-D-aspartate receptor) encephalitis: a rehabilitation perspective,” NeuroRehabilitation, vol. 30, no. 2, pp. 109–112, 2012. View at Publisher · View at Google Scholar · View at Scopus